|Articles|September 17, 2020
Nitrosamine Testing: The Regulatory Aspects
Author(s)SGS
Detection of N-Nitrosodimethylamine (NDMA) impurities has led to regulatory warnings and product recalls. Pharmaceutical manufacturers must adopt a proactive approach to risk assessment and mitigation in relation to genotoxic contaminants.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
Lilly Invests $3.5B in Pennsylvania Injectable Medicine Facility
2
PharmTech Weekly News Roundup – Week of January 26, 2026
3
Repertoire Immune Medicines and Lilly Collaborate on Treatments for Autoimmune Diseases
4
Vetter Announces Plan to Build Manufacturing Site in Germany with €1.5 Billion CDMO Investment
5